At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
DNA Ginkgo Bioworks Holdings Inc.
Market Closed 05-15 16:00:00 EDT
7.71
-0.14
-1.78%
盘后7.78
+0.07+0.91%
19:58 EDT
High7.82Low7.53Vol1.05M
Open7.58D1 Closing7.85Amplitude3.69%
Mkt Cap503.65MTradable Cap372.07MTotal Shares65.32M
T/O8.02MT/O Rate2.17%Tradable Shares48.26M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

DNA X, Inc. Delays Quarterly Filing After Asset Sale
TIPRANKS  ·  05-16 07:31
DNA X, Inc. Delays Quarterly Filing After Asset Sale
Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
prnewswire  ·  05-14 23:58
Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
Lotus Unveils Focus 2030 – Reinforcing Brand DNA with an All-New Hybrid-V8 Supercar
GlobeNewswire  ·  05-12
Lotus Unveils Focus 2030 – Reinforcing Brand DNA with an All-New Hybrid-V8 Supercar
Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), Xencor (XNCR) and Alto Neuroscience, Inc. (ANRO)
TIPRANKS  ·  05-11
Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), Xencor (XNCR) and Alto Neuroscience, Inc. (ANRO)
Is Inovio (INO) Turning Fresh DNA Medicine Data Into a More Coherent Investment Story?
Simply Wall St.  ·  05-10
Is Inovio (INO) Turning Fresh DNA Medicine Data Into a More Coherent Investment Story?
Ginkgo Bioworks Q1 revenue falls 49% on restructuring
Reuters  ·  05-08
Ginkgo Bioworks Q1 revenue falls 49% on restructuring
Ginkgo Bioworks reaffirms 2026 expected total cash burn of ($150M)-($125M)
TIPRANKS  ·  05-08
Ginkgo Bioworks reaffirms 2026 expected total cash burn of ($150M)-($125M)
Ginkgo Q1 FY26 net loss narrows 8.36% to $(76) million; revenue drops 49% to $19 million
Reuters  ·  05-08
Ginkgo Q1 FY26 net loss narrows 8.36% to $(76) million; revenue drops 49% to $19 million
Ginkgo Bioworks Holdings Q1 EPS $(1.39) Misses $(1.34) Estimate, Sales $19.474M Miss $41.520M Estimate
Benzinga  ·  05-08
Ginkgo Bioworks Holdings Q1 EPS $(1.39) Misses $(1.34) Estimate, Sales $19.474M Miss $41.520M Estimate
BRIEF-Ginkgo Bioworks Q1 Net Income USD -82.587 Million
Reuters  ·  05-08
BRIEF-Ginkgo Bioworks Q1 Net Income USD -82.587 Million
Ginkgo Bioworks Holdings Inc - Reaffirms 2026 Total Cash Burn Guidance of $(150)-$(125) Mln
THOMSON REUTERS  ·  05-08
Ginkgo Bioworks Holdings Inc - Reaffirms 2026 Total Cash Burn Guidance of $(150)-$(125) Mln
Press Release: Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
Dow Jones  ·  05-08
Press Release: Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
Ginkgo Bioworks Holdings Inc expected to post a loss of $1.08 a share - Earnings Preview
Reuters  ·  05-06
Ginkgo Bioworks Holdings Inc expected to post a loss of $1.08 a share - Earnings Preview
Ginkgo Bioworks to host first-quarter results presentation and Q&A session
Reuters  ·  04-30
Ginkgo Bioworks to host first-quarter results presentation and Q&A session
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
GlobeNewswire  ·  04-29
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
Eli Lilly Emerges as Top Contender in Pharma's AI Arms Race with $2.25 Billion Profluent Partnership for DNA Editing Tech
Stock News  ·  04-28
Eli Lilly Emerges as Top Contender in Pharma's AI Arms Race with $2.25 Billion Profluent Partnership for DNA Editing Tech
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
GlobeNewswire  ·  04-28
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
How to Avoid Fistfights and DNA Leaks at a World Leaders Summit -- WSJ
Dow Jones  ·  04-27
How to Avoid Fistfights and DNA Leaks at a World Leaders Summit -- WSJ
Uncovering the Hidden Lineage of Large Models: Fine-Tuning and Distillation Secrets Revealed
Deep News  ·  04-25
Uncovering the Hidden Lineage of Large Models: Fine-Tuning and Distillation Secrets Revealed
Nanobiotix Unveils Preclinical Data Showing Nanoprimer Boosts LNP-DNA Cancer Immunotherapy
TIPRANKS  ·  04-20
Nanobiotix Unveils Preclinical Data Showing Nanoprimer Boosts LNP-DNA Cancer Immunotherapy

Introduction

Company Name.
Ginkgo Bioworks Holdings Inc.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Issue price:
--